RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Royalty Pharma plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$60.27−0.69 (-1.13%)
Close on Oct 19, 2026
- Market cap
- $33.56B
- P/E (TTM)
- 34.2
- Dividend yield
- –
Share price
+$23.26 (+62.85%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsEx-dividend
Royalty Pharma plc grew revenue 10.0% to $2.54B over the twelve months to Jun 30, 2026. Operating income fell 17.9% to $1.51B, moving the operating margin from 79.8% to 59.6%.
Revenue
$2.54B
+10.0% vs. a year earlier
Operating income
$1.51B
-17.9% vs. a year earlier
EPS, diluted
$1.76
-19.3% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $33.56B
- P/E ratio
- 34.2
- Price to sales
- 13.24
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $2.54B
- Net income
- $815.00M
- EPS, diluted
- $1.76
- Diluted shares
- 557M
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
$2.54B+10.0% YoY
Operating income
$1.51B-17.9% YoY
Net income
$815.00M-20.4% YoY
EPS, diluted
$1.76-19.3% YoY
Reported periodTrailing twelve months